X-Linked Retinitis Pigmentosa (XLRP) Overview

Save information for later
Sign Up

Learn About X-Linked Retinitis Pigmentosa (XLRP)

View Main Condition: Retinitis Pigmentosa

What is the definition of X-Linked Retinitis Pigmentosa (XLRP)?
X-linked retinitis pigmentosa is a type of inherited eye disorder that affects the retina, causing progressive vision loss. X-linked retinitis pigmentosa is classified as non-syndromic because it occurs by itself instead of as part of other syndromes.
What are the symptoms of X-Linked Retinitis Pigmentosa (XLRP)?
Symptoms of X-linked retinitis pigmentosa include a loss of night vision in childhood; blind spots in the side, or peripheral, vision; tunnel vision; loss of central vision; and, eventually, blindness.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for X-Linked Retinitis Pigmentosa (XLRP)?
Treatment for X-linked retinitis pigmentosa involves the use of gene therapy made from adeno-associated viral vectors.
Who are the top X-Linked Retinitis Pigmentosa (XLRP) Local Doctors?
Advanced in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Rick A. Carpenter
Ophthalmology
Advanced in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Rick A. Carpenter
Ophthalmology
111 Aupuni St, 
Hilo, HI 
 (56.5 mi)
808-935-2964
Languages Spoken:
English
See accepted insurances

Rick Carpenter is an Ophthalmologist in Hilo, Hawaii. Dr. Carpenter and is rated as an Advanced provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are Cataract, Diabetic Retinopathy, Glaucoma, and Interstitial Keratitis.

Experienced in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Lynda M. Dolan
Family Medicine | Palliative Medicine
Experienced in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Lynda M. Dolan
Family Medicine | Palliative Medicine

Hilo Medical Center

1190 Waianuenue Ave, 
Hilo, HI 
 (54.3 mi)
808-932-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lynda Dolan is a Palliative Medicine provider in Hilo, Hawaii. Dr. Dolan and is rated as an Experienced provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). Her top areas of expertise are Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH), X-Linked Retinitis Pigmentosa (XLRP), and Relapsing Multiple Sclerosis (RMS).

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Stephen E. Clason
Ophthalmology
Advanced in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Stephen E. Clason
Ophthalmology
615 Piikoi St, Suite 1802, 
Honolulu, HI 
 (175.0 mi)
808-591-9393
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stephen Clason is an Ophthalmologist in Honolulu, Hawaii. Dr. Clason and is rated as an Advanced provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). His top areas of expertise are X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Cone Rod Dystrophy Amelogenesis Imperfecta, and Usher Syndrome Type 2A. Dr. Clason is currently accepting new patients.

View All Doctors
What are the latest X-Linked Retinitis Pigmentosa (XLRP) Clinical Trials?
An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Other, Biological
Study Phase: Phase 2

Summary: The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa
Who is this study for: Patients with X-Linked Retinitis Pigmentosa
Enrollment Status: Recruiting
Publish Date: February 11, 2025
Intervention Type: Biological, Drug
Study Drug: rAAV2tYF-GRK1-hRPGRco
Study Phase: Phase 2/Phase 3

Summary: This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.

View All Clinical Trials